kentucky semaglutide gi obstruction lawsuit glp-1 gastrointestinal attorney in kentucky gastrointestinal obstruction lawyer GLP-1 Attorneys kentucky glp-1 gastric intestinal obstruction

Report the product to the FDA MedWatch program at www.fda.gov/medwatch or by calling 1-800-FDA-1088

Eric Westman Approved in August 2024, Lercea GLP-1 Slimming & Health Nutrition Drops solution has shown promising results in the latest clinical trials

Dysregulated glucose levels, visceral fat accumulation, and other markers of poor metabolic function accelerate biological aging and increase the risk of chronic diseases, such as cardiovascular disease, Type 2 diabetes, and liver disease, making GLP-1s critical for overall health and healthspan

However, persistent or severe skin reactions, including blistering, significant swelling, or spreading rash, warrant immediate medical evaluation and may indicate contact dermatitis or allergic sensitization

If you are not seeing results after a few months of taking semaglutide, consult your healthcare provider and consider the following factors: Confirm whether you are on a full therapeutic dose or a low dose